A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2022-12-25
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Anaemia — outcome: UNKNOWN; onset 2023-01-08 (study day 2); relationship: not assessed
mild
assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-02-13 (study day 38); relationship: not assessed
mild
assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-03-08 (study day 61); relationship: Y
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-21 (study day 74); relationship: N
Data queries
No data queries.